Diabetes is one of the major diseases that currently endanger human health. Complications of macrovascular disease are the leading cause of death in diabetic patients, with nearly 80% of diabetic patients dying from cardiovascular disease. The mortality rate of cardiovascular disease in the diabetic population is at least 2-3 times higher than that of the general population. Diabetes is an equivocal risk for coronary heart disease (having diabetes is equivalent to having coronary heart disease). Patients with diabetes often have dyslipidemia prior to the onset of the disease, as evidenced by elevated triglycerides, reduced high-density cholesterol (good cholesterol), and mildly elevated low-density cholesterol (bad cholesterol). Numerous studies have illustrated that the causes of excessive risk of coronary heart disease in diabetic patients are multifaceted, including not only elevated blood glucose and blood pressure, but also diabetic dyslipidemia. Therefore, it is important to pay attention to the control of diabetic risk factors such as dyslipidemia. Among them, control of dyslipidemia is a crucial factor in reducing coronary heart disease, because dyslipidemia directly impairs arterial endothelial function and promotes the formation and development of atherosclerotic plaques. Large clinical studies have found that low-density cholesterol (LDL-C) is the first predictor of coronary heart disease in diabetic patients. For every 1 mmol/l reduction in LDL-C in diabetic patients, there was a 13% reduction in deaths from cardiovascular causes and a 21% reduction in strokes. Moreover, patients with type 2 diabetes with different baseline lipid levels benefit from the use of statin lipid-lowering drugs (XX statins, e.g., atorvastatin, simvastatin). It is reasonable to routinely apply statin therapy in diabetic patients. The primary goal of dyslipidemia treatment in diabetic patients should be to lower LDL-C. The basic goal for LDL-C control is less than 2.6 mmol/l, and for diabetic patients with existing coronary artery disease the LDL-C control goal is less than 1.8 mmol/l. Patients with type 2 diabetes should receive lipid-lowering therapy (preferably with statins) regardless of the presence of cardiovascular disease. Statins not only lower LDL-C (bad cholesterol), but also raise HDL-C (good cholesterol).